Trevi Therapeutics: Morgan Stanley Sees 143% Price Potential - Haduvio Could Represent an Opportunity in the Multi-Billion Dollar Market

Trevi Therapeutics Inc. (TRVI) is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine with extended-release formulation) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Chronic cough is a common condition affecting up to 85% of patients with IPF. There are approximately 150,000 patients with IPF in the U.S. The impact of chronic cough is significant, as patients may...